SB203580是一种p38 MAPK抑制剂,在THP-1细胞中IC50为0.3-0.5μM,对SAPK3(106T)和SAPK4(106T)选择性低10倍,且阻断PKB磷酸化,IC50为3-5μM。SB203580是第一个被报道的p38抑制剂。
保存方法:
Store at-20℃for one year(Powder);Store at 2-4℃for two weeks;Store at-20℃for six months after dissolution.
别名:
Adezmapimod;RWJ 64809
外观:
white to off-white powder
可溶性/溶解性:
DMSO:43 mg/mL(113.92 mM)
靶点:
p38 MAPK;PKB
In vitro(体外研究):
SB203580 inhibits the IL-2-induced proliferation of primary human T cells,murine CT6 T cells,or BAF F7 B cells with an IC50 of 3–5μm.SB203580 also inhibits IL-2-induced p70S6 kinase activation,although the concentration required is slightly higher with an IC50 above 10μm.SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10μm range.SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07μM,whereas inhibits total SAPK/JNK activity with an IC50 of 3–10μM.SB203580 at higher concentrations activates the ERK pathway,which subsequently enhances NF-κB transcriptional activity.SB203580 induces autophagy in human hepatocellular carcinoma(HCC)cells.
In vivo(体内研究):
SB203580 protects pig myocardium against ischemic injury in an in vivo model.SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus(SLE).
https://www.chem17.com/st343255/product_26487411.html
http://www.absin-reagents.com/Products-26487411.html